Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989，NSC-2260804

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Cited by 239 Publications

Cell, 2019, 176(6):1379-1392

PubMed: 30773315 ( click the link to review the publication )

Cancer Discov, 2019, 9(1):46-63

PubMed: 30266815 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 35(4):664-676

PubMed: 30991026 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):46-63

PubMed: 30581152 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(1):91-106

PubMed: 28457749 ( click the link to review the publication )

Nature, 2016, 539(7629):437-442

PubMed: 27642729 ( click the link to review the publication )

Nature, 2016, 532(7599):389-93

PubMed: 27064903 ( click the link to review the publication )

Nat Genet, 2014, 46(4):364-70

PubMed: 24584072 ( click the link to review the publication )

Cancer Cell, 2011, 19(6):792-804

PubMed: 21620777 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI124590

PubMed: 30830877 ( click the link to review the publication )

Autophagy, 2019, 15(6):1100-1111

PubMed: 30654687 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1606647

PubMed: 31007149 ( click the link to review the publication )

Leukemia, 2019, 33(1):181-190

PubMed: 29884903 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz073

PubMed: 31002307 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3413-3421

PubMed: 31216464 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(9):1282-1297

PubMed: 30767208 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

Am J Transplant, 2019, 19(5):1305-1314

PubMed: 30549430 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5322

PubMed: 31257577 ( click the link to review the publication )

Front Immunol, 2019, 10:524

PubMed: 30941147 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):77

PubMed: 31315616 ( click the link to review the publication )
J Antimicrob Chemother, 2019, 74(7):1921-1927

PubMed: 30934052 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):118

PubMed: 30987681 ( click the link to review the publication )

Xenotransplantation, 2019, 10.1111/xen.12522

PubMed: 31077480 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):41

PubMed: 30670079 ( click the link to review the publication )

J Immunol, 2019, 202(1):31-36

PubMed: 30518568 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2019, 169:266-272

PubMed: 30453174 ( click the link to review the publication )

J Cell Physiol, 2019, 234(7):12019-12028

PubMed: 30523643 ( click the link to review the publication )

Neurobiol Aging, 2019, 79:30-42

PubMed: 31026620 ( click the link to review the publication )

Neurobiol Aging, 2019, 80:127-137

PubMed: 31170533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 10.3389/fncel.2018.00515

PubMed: 30692914 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9805

PubMed: 31285446 ( click the link to review the publication )

JPEN J Parenter Enteral Nutr, 2019, 43(1):96-106

PubMed: 29761871 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(4):882-894

PubMed: 30906218 ( click the link to review the publication )

Food Chem Toxicol, 2019, 130:1-11

PubMed: 31054290 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108911

PubMed: 31079001 ( click the link to review the publication )

Mol Cell Endocrinol, 2019, 485:72-80

PubMed: 30735697 ( click the link to review the publication )

Cell Signal, 2019, 53:327-338

PubMed: 30389500 ( click the link to review the publication )

Life Sci, 2019, 217:243-250

PubMed: 30550889 ( click the link to review the publication )

J Cell Biochem, 2019, 120(3):3637-3650

PubMed: 30242894 ( click the link to review the publication )

Prostate, 2019, 79(2):206-214

PubMed: 30345525 ( click the link to review the publication )

Chem Biol Interact, 2019, 300:18-26

PubMed: 30611790 ( click the link to review the publication )

Am J Transl Res, 2019, 11(2):931-941

PubMed: 30899392 ( click the link to review the publication )

Am J Transl Res, 2019, 11(3):1616-1625

PubMed: 30972187 ( click the link to review the publication )

Am J Transl Res, 2019, 11(3):1473-1485

PubMed: 30972175 ( click the link to review the publication )
Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Drug Des Devel Ther, 2019, 13:1221-1231

PubMed: 31114162 ( click the link to review the publication )

Int J Mol Med, 2019, 44(2):457-468

PubMed: 31173197 ( click the link to review the publication )

Biosci Rep, 2019, 39(5)

PubMed: 29187584 ( click the link to review the publication )

Biosci Rep, 2019, 39(4)

PubMed: 30923227 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

Immunobiology, 2019, 224(3):455-461

PubMed: 30773287 ( click the link to review the publication )

Neurochem Res, 2019, 44(5):1090-1100

PubMed: 30712242 ( click the link to review the publication )

Neurochem Res, 2019, 44(2):347-356

PubMed: 30460641 ( click the link to review the publication )

Neurochem Res, 2019, 44(8):2007-2019

PubMed: 31325156 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 516(4):1265-1271

PubMed: 31301767 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:5003-5012

PubMed: 31303760 ( click the link to review the publication )

Exp Dermatol, 2019, 28(3):270-275

PubMed: 30650200 ( click the link to review the publication )

Connect Tissue Res, 2019, 60(4):323-334

PubMed: 30277081 ( click the link to review the publication )

Clin Interv Aging, 2019, 14:525-534

PubMed: 30880933 ( click the link to review the publication )

Connect Tissue Res, 2019, 10.1080/03008207

PubMed: 30782019 ( click the link to review the publication )

Animal, 2019, 10.1017/S1751731118003683

PubMed: 30616697 ( click the link to review the publication )

Mol Med Rep, 2019, 20(2):1523-1530

PubMed: 31257459 ( click the link to review the publication )

Med Sci Monit, 2019, 25:5389-5400

PubMed: 31325378 ( click the link to review the publication )

Viruses, 2019, 11(6)

PubMed: 31174294 ( click the link to review the publication )

J Gynecol Obstet Hum Reprod, 2019, 48(3):193-199

PubMed: 30553049 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6236-6247

PubMed: 30131384 ( click the link to review the publication )

Int J Cancer, 2018, 142(1):202-213

PubMed: 28905990 ( click the link to review the publication )
Cancer Lett, 2018, 436:28-37

PubMed: 30118842 ( click the link to review the publication )

Arch Toxicol, 2018, 92(10):3163-3173

PubMed: 30132043 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1063

PubMed: 30337536 ( click the link to review the publication )

FASEB J, 2018, 32(10):5602-5611

PubMed: 29718710 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(1):54-62

PubMed: 29996117 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 46(3):975-985

PubMed: 29680838 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2091-2099

PubMed: 30045927 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(6):1259-1270

PubMed: 29545332 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):330

PubMed: 30486857 ( click the link to review the publication )

J Mol Med (Berl), 2018, 96(8):807-817

PubMed: 29959473 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386287 ( click the link to review the publication )

Front Pharmacol, 2018, 9:877

PubMed: 30135653 ( click the link to review the publication )

Biomed Pharmacother, 2018, 99:271-277

PubMed: 29334671 ( click the link to review the publication )

J Dermatol Sci, 2018, 92(2):172-180

PubMed: 30220530 ( click the link to review the publication )

J Environ Sci (China), 2018, 66:182-187

PubMed: 29628085 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

J Cell Biochem, 2018, 10.1002/jcb.27481

PubMed: 30206977 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):291-298

PubMed: 29355493 ( click the link to review the publication )

Am J Transl Res, 2018, 10(4):1229-1236

PubMed: 29736216 ( click the link to review the publication )

Exp Gerontol, 2018, 114:57-66

PubMed: 30399406 ( click the link to review the publication )

Toxicol Lett, 2018, 289:28-41

PubMed: 29518472 ( click the link to review the publication )

Int Immunopharmacol, 2018, 64:308-318

PubMed: 30243066 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):425-433

PubMed: 29749504 ( click the link to review the publication )
Drug Des Devel Ther, 2018, 12:2971-2980

PubMed: 30254426 ( click the link to review the publication )

PLoS One, 2018, 13(9):e0203402

PubMed: 30192802 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):166-172

PubMed: 29792861 ( click the link to review the publication )

Mol Cell Biochem, 2018, 445(1-2):135-143

PubMed: 29299747 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Neurol Res, 2018, 10.1080/01616412

PubMed: 30325723 ( click the link to review the publication )

Mol Med Rep, 2018, 17(3):4307-4316

PubMed: 29363725 ( click the link to review the publication )

Mol Med Rep, 2018, 18(2):1405-1414

PubMed: 29845247 ( click the link to review the publication )

Mol Med Rep, 2018, 18(2):1485-1494

PubMed: 29901107 ( click the link to review the publication )

Arch Med Res, 2018, 49(6):381-390

PubMed: 30573200 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2339-2349

PubMed: 29667627 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):8223-8230

PubMed: 29805556 ( click the link to review the publication )

Am J Med Sci, 2018, 356(2):168-176

PubMed: 30219159 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(3):457-465

PubMed: 29298915 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.23525

PubMed: 28524818 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):162

PubMed: 29145888 ( click the link to review the publication )

Br J Cancer, 2017, 117(8):1139-1153

PubMed: 29017179 ( click the link to review the publication )

Front Immunol, 2017, 8:1507

PubMed: 29250056 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 42(5):1755-1768

PubMed: 28746918 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Mol Neurobiol, 2017, 54(3):1710-1724

PubMed: 26873855 ( click the link to review the publication )

J Cancer, 2017, 8(4):555-562

PubMed: 28367235 ( click the link to review the publication )
J Cell Mol Med, 2017, 21(11):2896-2908

PubMed: 28544376 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(12):3420-3434

PubMed: 28643395 ( click the link to review the publication )

Front Cell Neurosci, 2017, 11:303

PubMed: 29033791 ( click the link to review the publication )

Am J Pathol, 2017, 187(8):1736-1749

PubMed: 28627412 ( click the link to review the publication )

Mol Carcinog, 2017, 56(5):1427-1437

PubMed: 27996156 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:56

PubMed: 28293544 ( click the link to review the publication )

Am J Transl Res, 2017, 9(5):2077-2087

PubMed: 28559962 ( click the link to review the publication )

J Cancer, 2017, 8(12):2163-2172

PubMed: 28819418 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):385-392

PubMed: 28623128 ( click the link to review the publication )

Exp Dermatol, 2017, 26(5):409-415

PubMed: 27762043 ( click the link to review the publication )

Biomed Res Int, 2017, 2017:6341919

PubMed: 28265573 ( click the link to review the publication )

Cancer Genomics Proteomics, 2017, 14(1):83-91

PubMed: 28031240 ( click the link to review the publication )

Mol Med Rep, 2017, 16(5):7237-7244

PubMed: 28944847 ( click the link to review the publication )

Exp Ther Med, 2017, 14(1):748-752

PubMed: 28672994 ( click the link to review the publication )

Kaohsiung J Med Sci, 2017, 33(7):321-326

PubMed: 28738971 ( click the link to review the publication )

Blood Adv, 2017, 1(14):947-960

PubMed: 29296736 ( click the link to review the publication )

Sci Rep, 2017, 7(1):6529

PubMed: 28747804 ( click the link to review the publication )

Oncotarget, 2017, 8(20):32977-32989

PubMed: 28380429 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47574-47585

PubMed: 28548933 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10270

PubMed: 28860495 ( click the link to review the publication )

Comp Biochem Physiol C Toxicol Pharmacol, 2017, 195:52-59

PubMed: 28223193 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95332-95345

PubMed: 29221131 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )
Cancer Res, 2016, 76(5):1112-21

PubMed: 26701805 ( click the link to review the publication )

Int J Cancer, 2016, 138(8):2013-20

PubMed: 26566757 ( click the link to review the publication )

Diabetes, 2016, 65(4):927-41

PubMed: 26858361 ( click the link to review the publication )

Redox Biol, 2016, 10:78-89

PubMed: 27697670 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.150

PubMed: 27132509 ( click the link to review the publication )

Free Radic Biol Med, 2016, 90:230-42

PubMed: 26593748 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(11):e933

PubMed: 27801893 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1861(3):177-87

PubMed: 26692031 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(10):1555-68

PubMed: 26976639 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

Tissue Eng Part A, 2016, 22(17-18):1075-85

PubMed: 27477105 ( click the link to review the publication )

Acta Pharmacol Sin, 2016, 10.1038/aps.2016.31

PubMed: 27264314 ( click the link to review the publication )

Cell Signal, 2016, 28(8):1086-98

PubMed: 27185187 ( click the link to review the publication )

World J Gastroenterol, 2016, 22(18):4501-14

PubMed: 27182160 ( click the link to review the publication )

Am J Transl Res, 2016, 8(6):2667-80

PubMed: 27398150 ( click the link to review the publication )

J Cancer, 2016, 7(11):1431-40

PubMed: 27471559 ( click the link to review the publication )

Oncol Rep, 2016, 35(6):3705-13

PubMed: 27035419 ( click the link to review the publication )

Dig Dis Sci, 2016, 61(8):2272-83

PubMed: 27010547 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 470(2):324-330

PubMed: 26792718 ( click the link to review the publication )

Vet Microbiol, 2016, 193:22-7

PubMed: 27599926 ( click the link to review the publication )

Transl Neurosci, 2016, 7(1):50-55

PubMed: 28123821 ( click the link to review the publication )
Anticancer Drugs, 2016, 27(7):635-42

PubMed: 27176035 ( click the link to review the publication )

Anticancer Res, 2016, 36(11):5849-5858

PubMed: 27793908 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):1071-8

PubMed: 26271666 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):341-51

PubMed: 26219891 ( click the link to review the publication )

Comp Biochem Physiol A Mol Integr Physiol, 2016, 198:15-21

PubMed: 27040186 ( click the link to review the publication )

J Hepatol, 2015, 10.1016/j.jhep.2015.11.011

PubMed: 26592953 ( click the link to review the publication )

Autophagy, 2015, 10.1080/15548627.2015.1023982

PubMed: 25906440 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.01.014

PubMed: 25660019 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

Oncogene, 2015, 34(2):263-8

PubMed: ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.226

PubMed: 26165839 ( click the link to review the publication )

Cancer Lett, 2015, 357(2):468-75

PubMed: 25444920 ( click the link to review the publication )

J Pathol, 2015, 235(5):672-85

PubMed: ( click the link to review the publication )

Neurobiol Dis, 2015, 82:516-525

PubMed: 26388397 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: ( click the link to review the publication )

J Cell Mol Med, 2015, 10.1111/jcmm.12473

PubMed: 25754106 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.03.014

PubMed: 25850000 ( click the link to review the publication )

J Biol Chem, 2015, 290(29):18102-10

PubMed: 26055714 ( click the link to review the publication )

J Biol Chem, 2015, 289(46):31950-9

PubMed: 25278019 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(1):125-139

PubMed: 25628925 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):71-80

PubMed: 25955301 ( click the link to review the publication )

Exp Cell Res, 2015, 331(1):97-104

PubMed: 25447203 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )
BMC Cancer, 2015, 15(1):255

PubMed: 25886314 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):241

PubMed: 25884680 ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:993-1026

PubMed: 25733817 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

DNA Cell Biol, 2015, 34(10):610-7

PubMed: 26284306 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(22):6635-47

PubMed: 25252916 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.355

PubMed: 25362851 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2450-62

PubMed: 25053822 ( click the link to review the publication )

Mol Cancer Res, 2014, 10.1158/1541-7786.MCR-14-0153-T

PubMed: 25349289 ( click the link to review the publication )

J Immunol, 2014, 192(8):3958-68

PubMed: 24634494 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(2):372-86

PubMed: 24184209 ( click the link to review the publication )

Biochem Pharmacol, 2014, 89(1):74-85

PubMed: 24607273 ( click the link to review the publication )

Ann Surg Oncol, 2014, 21(1):179-88

PubMed: 23907312 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )

Mediators Inflamm, 2014, 2014:868753

PubMed: 25045214 ( click the link to review the publication )

Mol Brain, 2014, 7:45

PubMed: 24935155 ( click the link to review the publication )

Transl Oncol, 2014, 10.1016/j.tranon.2014.02.007

PubMed: 24742865 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87281

PubMed: 24489888 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )
BMC Biotechnol, 2014, 14:04

PubMed: 24438107 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 454(2):328-34

PubMed: 25450397 ( click the link to review the publication )

Comp Biochem Physiol A , 2014, 168:25-39

PubMed: 24269559 ( click the link to review the publication )

MOL VIS, 2014, 20:1161-1173

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Exp Transl Stroke Med, 2014, 6:8

PubMed: 24991402 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(33):13588-93

PubMed: 23898208 ( click the link to review the publication )

Cancer Res, 2013, 73(17):5449-58

PubMed: 23832664 ( click the link to review the publication )

J Hematol Oncol, 2013, 6:18

PubMed: 23415012 ( click the link to review the publication )

Development, 2013, 140(15):3254-65

PubMed: 23861062 ( click the link to review the publication )

Mol Oncol, 2013, 8(3):469-82

PubMed: 24444656 ( click the link to review the publication )

Cancer Sci, 2013, 104(7):810-6

PubMed: 23510069 ( click the link to review the publication )

Ann Thorac Surg, 2013, 95(5):1768-75

PubMed: 23561805 ( click the link to review the publication )

PLoS One, 2013, 8(8): e72053

PubMed: 23991038 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70804

PubMed: 23936469 ( click the link to review the publication )

Onco Targets Ther, 2013, 6:1373-84

PubMed: 24124380 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(1):9-17

PubMed: 23946753 ( click the link to review the publication )

Cell Res, 2012, 22(6):1003-21

PubMed: 22430150 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1833(3):652-62

PubMed: 23228564 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

J Toxicol Sci, 2012, 37(4):813-21

PubMed: 22863860 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(22):7116-26

PubMed: 21976531 ( click the link to review the publication )

J Lipid Res, 2011, 52(9):1617-25

PubMed: 21757781 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Targets

mTOR ^[1]
(HEK293 cells)

~0.1 nM

In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. ^[1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. ^[2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT-29	MYDDfZRwfG:6aXOgRZN{[Xl?	NHXOeFYyOCCwTR?=	M{LVVVczKGh?	NXzoZolRTE2VTx?=	M4\yXHBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=>	NVjJdpZ{OjR7MEC4O\|M>
HT-29	NUHGcpJOS3m2b4TvfIlkKEG\|c3H5	NVXvSZN4OTBibl2=	MWG3NkBp	NX3a[lFQTE2VTx?=	MVTQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl?	NFXTN2IzPDlyMEi3Ny=>
HT-29	NVrKfXM5S3m2b4TvfIlkKEG\|c3H5	Ml73NVAhdk1?	NXLzSoRHPzJiaB?=	NGjXeHhFVVOR	MmrZVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk>	NX:5O\|g5OjR7MEC4O\|M>
PC3	MlT0T4lv[XOnIFHzd4F6	MUOxNFAhdk1?	NWHVR4d4OSCq	M{OzeWROW09?	NVPJOFN7WG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4>	MoP0NlE6Pzh4OEO=
PC3	NETrR\|JMcW6jc3WgRZN{[Xl?	NIf3N2cyODBibl2=	NGHJN3EyKGh?	MnL2SG1UVw>?	MkW4SI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?	NHnFOZgzOTl5OE[4Ny=>
PC3	MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIT4dIgyNjVizszN	NWrhSHdOOSCq	NF76UnJFVVOR	Mn7LTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P	M3XK[lIyQTd6Nkiz
HEK293	NYDk[HF{TnWwY4Tpc44hSXO\|YYm=	Mnv3NVAxKG6P	NYi5[m9tQCCq	MnzCSG1UVw>?	M{jk[mlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?=	M4\xSFIyPTN7M{Cx
BT-20	MoTYT4lv[XOnIFHzd4F6	Mmr0NlAh\|ryP		NUjTUZVpTE2VTx?=	Moq0SI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25?	NXn5T3pkOjF\|NUO1OVE>
U937	M{njOWFvfGmkYXP0[ZJq[WxiQYPzZZk>	MmDnOVAh\|ryP	NXHvWGZzPDhiaB?=	MnS4SG1UVw>?	NXTDUJlVUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzz	Ml;3NlEyPDJzME[=
U937	NWXub\|RUSW62aXLhZ5RmemmjbDDBd5NigQ>?	NYSxe4E6PTBizszN	MYq0PEBp	NEHLW4VFVVOR	M17wSmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ\|Mj2yJIlvKFV7M{egZ4VtdHN?	MVqyNVE1OjFyNh?=
U937	MnLFRY51cWKjY4TldolidCCDc4PhfS=>	MW[1NEDPxE1?	MVe0PEBp	M2XjOmROW09?	MnLESI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM>	MVKyNVE1OjFyNh?=
MCF-7	NUjKcVlOSXW2b4DoZYd6KEG\|c3H5	NUHyWWZWOzBibl2=	MYS0JIg>	NV\GU3BITE2VTx?=	M3\nVWlv\HWlZYOgZZV1d3CqYXf5	NHjQ[FIzODB{OEGzOC=>
U87MG	MlrKT4lv[XOnIFHzd4F6	NWrjUY53OSEQvF2=	NV\sT4VHPiCq	NUiybGlHTE2VTx?=	NUnqT3pPWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:\|cHjvdplt[XSrb36=	MVuxPVg1QDRyNB?=
U87MG	NW\XV3ZiU2mwYYPlJGF{e2G7	NVHY[3hwOSEQvF2=	MXu2JIg>	NHHUe4dFVVOR	M1XvPXBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u	MnvYNVk5PDh2MES=
U87MG	MYPLbY5ie2ViQYPzZZk>	NHjG[WcyKM7:TR?=	NUTSeI1WPiCq	MVrEUXNQ	Mk\RSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?	MkHiNVk5PDh2MES=
U87MG	NI[4bXZMcW6jc3WgRZN{[Xl?	MoDsNUDPxE1?	M4KxRVYhcA>?	M{TMcGROW09?	MXzEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M\|Q3MSCyaH;zdIhwenmuYYTpc44>	MVOxPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb	M{ntcGF2fG:yaHHnfUBCe3OjeR?=	MYCwMlIh\|ryP	M4HTflI1KGh?	NUXhPZhnTE2VTx?=	Mm\RTY5lfWOnczDheZRweGijZ4m=	NX74e\|ZEOTh\|OUG5OFk>
COS7 cells expressing EGFP-LC3	Mnu0RZV1d3CqYXf5JGF{e2G7	NVu5TWdLOC5{IN88US=>	NWGyV5c2OjRiaB?=	NWTrbZZ[TE2VTx?=	MnjBTY5lfWOnczDheZRweGijZ4m=	MWGxPFM6OTl2OR?=
H4	NW[2Z3lmTnWwY4Tpc44hSXO\|YYm=	NGDtPZQxNjJizszN	NIX3cWYzPCCq	MXfEUXNQ	MnHSTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=>	MmL4NVgxOjR3OES=
HeLa	M4j3cGZ2dmO2aX;uJGF{e2G7	NE[5b2YyODBibl2=	NHXKVJQ{PiCq	MmC3SG1UVw>?	NEHEfFhKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v	MnLlNVc2PjN\|OEW=
HeLa	M2[5dWZ2dmO2aX;uJGF{e2G7	M4[0VlExOCCwTR?=	M4\DR\|M3KGh?	MVTEUXNQ	NIjCPVJKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25?	NH\tZW4yPzV4M{O4OS=>
HeLa	NFfRNotHfW6ldHnvckBCe3OjeR?=	M3\6c\|ExOCCwTR?=	NFH1PWg{PiCq	MljYSG1UVw>?	NYC1Z4JbUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v	NI\SN4syPzV4M{O4OS=>
SYF	MXfGeY5kfGmxbjDBd5NigQ>?	MlPJNVAxKG6P	M1;DdFI1KGh?	MUnEUXNQ	MX7JcoR2[2W\|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36=	NIrlUIUyPzV4M{O4OS=>
SYF	M4PDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYX1N29xOTByIH7N	Mlf3NlQhcA>?	NV3LUHNRTE2VTx?=	NFnzV5BKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz	MV:xO\|U3OzN6NR?=
HEK293T	MV7BcpRqfmm{YXygRZN{[Xl?	Mn\GNUBvVQ>?	MUW0JIQ>	M1TtSmROW09?	MnXnTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2=	M3m5VFE4PDh3NUCx
HEK293T	Mn7aRY51cX[rcnHsJGF{e2G7	NF[0enAyKG6P	NHnoPGQ1KGR?	MYHEUXNQ	NIP1fZpKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=>	M4[0V\|E4PDh3NUCx
PBMC	MVnGeY5kfGmxbjDBd5NigQ>?	NFnSfokyKG6P	M4fOcVE1KGR?	MUnEUXNQ	MoP4VoVlfWOnczDDR3I2KGSnboPpeJk>	NEnhboQyPzR6NUWwNS=>
PBMC	NXLpb25pTnWwY4Tpc44hSXO\|YYm=	MXqxJI5O	M3L2[lE1KGR?	NHTubWVFVVOR	MWnEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=>	MXWxO\|Q5PTVyMR?=
HEK293 cells	NWH2R3pwU2mwYYPlJGF{e2G7	NF\ONlM2OCCwTR?=	M{S4[VQ2KG2rbh?=	MlToSG1UVw>?	NXuyUnYxUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?=	M2LiRlE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc	M2DwZmZ2dmO2aX;uJGF{e2G7	MoTwNVAxKG6P	MoWzOEBp	M3zHdWROW09?	NHvHfIlKdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:\|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>?	NXX2[GtoOTdzMkiyOlI>
Human mixed lymphocyte	NYjjTFJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\KVGFEPSCwTR?=		M{DobGROW09?	NGTSN3VKSzVyPUGuOkBvVS5?	MnPDNVYyQDV6NkW=
Lewis rat lymph node cells	M3HUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTMNnpVPSEQvF2=		M4XtcWROW09?	NU\rUYN[UUN3ME2yMlYh\|ryP	NH;L[o8yPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice	M4\BRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYmxNEBvVQ>?	M{K1OFczKGh?	NY\TUY93TE2VTx?=	Mn;5TY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?=	NIjzZ5IyODB{MUm0PC=>
MRK-nu-1	NEfSOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTBwOES1JJBO	NInEXVZUSU6JRWK=
OCUB-M	NYXpbGxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUSwTlNQUUN3ME21MlI1KHCP	NY\yOoxPW0GQR1XS
SF539	MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXITWM2OD1zMT62JJBO	MVXTRW5ITVJ?
ES4	NWjwbWhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDiTWM2OD1{MT61JJBO	MUHTRW5ITVJ?
RL95-2	M2Xs[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTFyNzDwUS=>	NVTlR4FmW0GQR1XS
LC-2-ad	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDqTWM2OD12MkOgdG0>	MnG3V2FPT0WU
Daudi	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTxcHRKSzVyPUSzOEBxVQ>?	NUnOV5lxW0GQR1XS
NTERA-S-cl-D1	NEH6PHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorJTWM2OD12NEOgdG0>	NI\0WGNUSU6JRWK=
OS-RC-2	NHG1UndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXuXIpKSzVyPU[1NkBxVQ>?	MomzV2FPT0WU
VA-ES-BJ	MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTd{MzDwUS=>	M3P3W3NCVkeHUh?=
GR-ST	M1r5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTh2NjDwUS=>	M3TBdHNCVkeHUh?=
SW872	NVjrS2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPSTWM2OD16NE[gdG0>	MYjTRW5ITVJ?
NOS-1	NGP6bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrjTWM2OD16N{GgdG0>	NYPEeHVNW0GQR1XS
MC116	NXGwRldOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;Xbo1sUUN3ME25PFUheE1?	M3XmS3NCVkeHUh?=
NCI-H1355	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7lPIlKSzVyPUGuNFEhdk1?	NGrP[o5USU6JRWK=
RPMI-8226	Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHYNIhyUUN3ME2xMlE6KG6P	NWHZRY9nW0GQR1XS
TE-15	NGj4[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLGXYJDUUN3ME2xMlM3KG6P	NVKwfJRuW0GQR1XS
Ramos-2G6-4C10	Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfT[XV5UUN3ME2xMlQ3KG6P	NYnEUXVDW0GQR1XS
KU812	Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJwMEGgcm0>	NVPkfJZIW0GQR1XS
EW-1	MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGe3XmdKSzVyPUKuNVchdk1?	MUjTRW5ITVJ?
KS-1	NEfWSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vC[WlEPTB;Mj60OUBvVQ>?	NEOwcGJUSU6JRWK=
SK-LMS-1	M2PIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrzTWM2OD1{LkS5JI5O	MWjTRW5ITVJ?
TGBC1TKB	NV;6dnlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TqZWlEPTB;Mj62PUBvVQ>?	NFLySI9USU6JRWK=
TE-6	M4HvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTGZ4NIUUN3ME2yMlc4KG6P	M4nuUXNCVkeHUh?=
ETK-1	NIDGZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH33RmpKSzVyPUKuPFIhdk1?	M2PPWnNCVkeHUh?=
BE-13	NUPRcWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTaeZFKSzVyPUKuPVkhdk1?	M4HM[nNCVkeHUh?=
A3-KAW	Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jIPWlEPTB;Mj65PUBvVQ>?	NHfkfGtUSU6JRWK=
TE-10	M2DLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTNwMzDuUS=>	NEDRXldUSU6JRWK=
DOHH-2	M3;EWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnwcJRzUUN3ME2zMlM2KG6P	NIrnOWlUSU6JRWK=
ES6	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrlfI1KSzVyPUOuOFMhdk1?	M4HNZXNCVkeHUh?=
OPM-2	NELMb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGr3UI1KSzVyPUSuNVUhdk1?	MoDtV2FPT0WU
SH-4	Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTRwM{Sgcm0>	MYrTRW5ITVJ?
NB13	M3rvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTRwM{[gcm0>	MWLTRW5ITVJ?
HUTU-80	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYflPZpVUUN3ME20MlQzKG6P	MWfTRW5ITVJ?
CCRF-CEM	MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTRwOUSgcm0>	NEPNS2tUSU6JRWK=
TGBC24TKB	M33GR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\ONWlEPTB;NT61NUBvVQ>?	Mnz5V2FPT0WU
697	NXj3cFc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3OfmozUUN3ME22MlI5KG6P	NXXF[ZhPW0GQR1XS
J-RT3-T3-5	M2HhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7UO2xKSzVyPU[uOFYhdk1?	M3mzXXNCVkeHUh?=
KALS-1	MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1i5RWlEPTB;Nj61OkBvVQ>?	Mo[xV2FPT0WU
no-10	M3rDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTXTWM2OD15LkK5JI5O	MVnTRW5ITVJ?
SK-NEP-1	M4jhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjlTYxlUUN3ME24Mlc6KG6P	NX3ucHNEW0GQR1XS
L-540	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17l[WlEPTB;MUCuOFIhdk1?	NWnDdHROW0GQR1XS
JiyoyeP-2003	NUHmOYROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\sW2lEPTB;MUCuPVQhdk1?	MlzwV2FPT0WU
HH	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDaTWZVUUN3ME2xNU4{QSCwTR?=	MnHPV2FPT0WU
SR	M2XBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PRNGlEPTB;MUGuOFUhdk1?	NFrZVZJUSU6JRWK=
QIMR-WIL	NEL6UFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGm0eppKSzVyPUGxMlg2KG6P	NU\rfmozW0GQR1XS
A4-Fuk	NH7oeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPBWnlKSzVyPUGzMlEzKG6P	NV23cYRFW0GQR1XS
CESS	M33PS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITN[FNKSzVyPUGzMlE{KG6P	M{jqUHNCVkeHUh?=
KE-37	NE[zU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DNVGlEPTB;MU[uNFchdk1?	MlK1V2FPT0WU
SK-UT-1	NWrjcIZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7BTWM2OD1zNj64NUBvVQ>?	M4r1cXNCVkeHUh?=
SIG-M5	NIfVPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXIcXI2UUN3ME2xO{4zPSCwTR?=	NITndGtUSU6JRWK=
HT	NVPpVlAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTF5Lk[gcm0>	Mn;5V2FPT0WU
DEL	M2\XfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33vW2lEPTB;MUeuPVkhdk1?	MUDTRW5ITVJ?
SK-PN-DW	M2PiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXZXIhKSzVyPUKwMlI{KG6P	NHr0eGxUSU6JRWK=
RPMI-8402	NIrncFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIT6V\|hKSzVyPUKxMlc4KG6P	NH\ZNHdUSU6JRWK=
RPMI-6666	M2LoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TLfWlEPTB;MkSuOFIhdk1?	M4G3U3NCVkeHUh?=
NCI-H720	NEPkXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTJ3LkSxJI5O	NEXRRWJUSU6JRWK=
EW-16	NH6xT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzVTWM2OD1{Nj64O{BvVQ>?	MWfTRW5ITVJ?
BL-70	MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTkV3JzUUN3ME2yPE4{QCCwTR?=	NI\BOFlUSU6JRWK=
SF126	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHKw[YJKSzVyPUOwMlM5KG6P	NH3JcoJUSU6JRWK=
BC-1	M2XD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HQO2lEPTB;M{GuNlYhdk1?	M2LZT3NCVkeHUh?=
MHH-PREB-1	NF\5R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mof1TWM2OD1\|Mj60OEBvVQ>?	MYTTRW5ITVJ?
A101D	NEnKbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XE[WlEPTB;M{KuOlIhdk1?	Mli1V2FPT0WU
NMC-G1	MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\L[mlEPTB;M{OuOlchdk1?	NGHNZ2tUSU6JRWK=
LB1047-RCC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTN2Lk[5JI5O	MlvFV2FPT0WU
EM-2	M4nwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVi5e5hOUUN3ME2zPE42OyCwTR?=	NGWyeplUSU6JRWK=
COLO-684	MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTN7Lkigcm0>	NWLiVZZoW0GQR1XS
Becker	M4LzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTRzLkC1JI5O	MorEV2FPT0WU
BL-41	M1j3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{S0UWlEPTB;NEOuOlYhdk1?	NXzjOIN1W0GQR1XS
MDA-MB-134-VI	MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYH0UFJLUUN3ME20OE4xOiCwTR?=	NHfNWWJUSU6JRWK=
L-363	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTR2LkezJI5O	MX;TRW5ITVJ?
ECC4	NUiyRotvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTR2Lke4JI5O	Mo\EV2FPT0WU
A388	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTR2LkiyJI5O	MmjjV2FPT0WU
HEL	M1\mdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvpTWM2OD12OT63PUBvVQ>?	MkfIV2FPT0WU
RKO	M2fhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTVyLkK5JI5O	MnviV2FPT0WU
KINGS-1	MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFSxVIRKSzVyPUWxMlU2KG6P	MmfFV2FPT0WU
EB-3	NXXKZmhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkO0TWM2OD13Mj62O{BvVQ>?	MUnTRW5ITVJ?
ARH-77	NUT1[3R[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrUe3VKSzVyPUWyMlghdk1?	M3nscHNCVkeHUh?=
GCIY	M2fWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTV\|LkS2JI5O	NXfTeZhvW0GQR1XS
NCI-H1304	NEL4b5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTV5LkKyJI5O	NV\uVGR[W0GQR1XS
KARPAS-299	M4jERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTzR3lKSzVyPU[xMlgzKG6P	NULOT4huW0GQR1XS
IA-LM	NUDYcnBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnITWM2OD14OD6xN{BvVQ>?	M120NHNCVkeHUh?=
GI-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXn2W5lOUUN3ME23NE4{QSCwTR?=	M1HNd3NCVkeHUh?=
TE-11	M3nZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXrZY5EUUN3ME23O{4yPyCwTR?=	Mnv5V2FPT0WU
LS-411N	NUPuWWdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rZS2lEPTB;N{euOVchdk1?	M1PXVnNCVkeHUh?=
no-11	NWfJSWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTh\|LkK0JI5O	MlzkV2FPT0WU
MV-4-11	M3:0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mke1TWM2OD16Mz63N{BvVQ>?	MWfTRW5ITVJ?
BV-173	NF3qXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3WTWM2OD16Mz65O{BvVQ>?	M1vKW3NCVkeHUh?=
CMK	NXG3Nm85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fpW2lEPTB;OESuNVYhdk1?	M1nhdXNCVkeHUh?=
LC4-1	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjLTWM2OD16Nj63NkBvVQ>?	M1izdnNCVkeHUh?=
COR-L279	NULKcoZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHzTWM2OD16Nz6yOUBvVQ>?	NXPBO2xIW0GQR1XS
NCI-H209	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;ITodKSzVyPUi3MlQyKG6P	M2nxWnNCVkeHUh?=
Raji	M2DLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHMTWM2OD16OT63NkBvVQ>?	MWnTRW5ITVJ?
LB996-RCC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPUTWM2OD17Mz60N{BvVQ>?	MojrV2FPT0WU
NCI-H526	NV\WZXhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGD2PHlKSzVyPUmzMlU6KG6P	NVWyU2FyW0GQR1XS
KGN	NWeybYRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTl4LkK5JI5O	MkLMV2FPT0WU
MOLT-4	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoX6TWM2OD17Nj63PUBvVQ>?	M3rEdXNCVkeHUh?=
PF-382	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnJTWM2OD17Nj63PUBvVQ>?	MoXLV2FPT0WU
BC-3	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTl7LkG4JI5O	NIi4TXZUSU6JRWK=
KARPAS-422	NF;mdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF35cGtKSzVyPUGwNk4xQSCwTR?=	M4n4fnNCVkeHUh?=
SBC-1	NXnZVFh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTFyNz63OUBvVQ>?	NY\lWnA1W0GQR1XS
LC-1F	NFOwOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoS3TWM2OD1zMEiuNFUhdk1?	NFf4NVBUSU6JRWK=
GB-1	MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTFyOT6wNkBvVQ>?	MnzzV2FPT0WU
SNB75	MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTFzOT62PUBvVQ>?	MnfqV2FPT0WU
BB65-RCC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrH[I9KSzVyPUGxPU46OyCwTR?=	MnG5V2FPT0WU
NCI-N87	MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfXdYFJUUN3ME2xNlEvQThibl2=	M3rsfXNCVkeHUh?=
IST-MEL1	M1[2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTF{Mj6zPEBvVQ>?	M4Dhe3NCVkeHUh?=
HOP-62	M1;NeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jmVWlEPTB;MUK2Mlg6KG6P	M2LpSHNCVkeHUh?=
ACN	MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4[wdmlEPTB;MUS2Mlc2KG6P	MYPTRW5ITVJ?
DMS-114	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXUTWM2OD1zNUCuOlchdk1?	NHfDNpJUSU6JRWK=
MLMA	M4j3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jsNWlEPTB;MUW5Mlg5KG6P	NGrIcGFUSU6JRWK=
HT-144	NXXrd3NuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrLV3hLUUN3ME2xOlUvPDNibl2=	MnizV2FPT0WU
C2BBe1	NGjEemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTF4Nz63OkBvVQ>?	MYLTRW5ITVJ?
L-428	NWfu[FM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTF5Nz63JI5O	M3:yd3NCVkeHUh?=
DU-4475	NUDHUo5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrrOHRnUUN3ME2xPFcvPjhibl2=	NEDQVG1USU6JRWK=
CP67-MEL	M33nSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17rR2lEPTB;MUm5MlM5KG6P	NGrZXWRUSU6JRWK=
MEG-01	NI\YNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTJyMT65OkBvVQ>?	MYrTRW5ITVJ?
IST-SL2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEP4XFVKSzVyPUKwPE43OyCwTR?=	NInSXG5USU6JRWK=
ES8	M{TMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzZfIZKSzVyPUKyOU46PCCwTR?=	NHPBc4lUSU6JRWK=
COLO-800	M{fjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzEc3l3UUN3ME2yN\|UvOjhibl2=	NVrEV\|ZTW0GQR1XS
MFH-ino	M3\U[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXZTZdtUUN3ME2yN\|UvQDRibl2=	NVKydmxbW0GQR1XS
OVCAR-4	M1vMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnwSmtEUUN3ME2yN\|cvOjRibl2=	MUTTRW5ITVJ?
PSN1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;hb2hKSzVyPUK0Nk44OSCwTR?=	NFjmUoZUSU6JRWK=
EW-12	MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fM[GlEPTB;MkSzMlEhdk1?	M{LJSXNCVkeHUh?=
HCC1599	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTJ4MT60O{BvVQ>?	MX\TRW5ITVJ?
SJSA-1	MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NES2NZFKSzVyPUK3NU41PiCwTR?=	NXXxemdbW0GQR1XS
ST486	MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUKwXYV6UUN3ME2yPVYvOTRibl2=	M1njdnNCVkeHUh?=
NOMO-1	NVvKOmFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;MXoVWUUN3ME2zNFAvOjFibl2=	MkTwV2FPT0WU
MN-60	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPuTWM2OD1\|MEWuN\|Ihdk1?	M2jOWXNCVkeHUh?=
HCC1187	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk[4TWM2OD1\|MEeuNlUhdk1?	NYLCc3JpW0GQR1XS
SW982	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXkWJdKSzVyPUOxOE44PSCwTR?=	NEnQW3VUSU6JRWK=
LB647-SCLC	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrzUWxxUUN3ME2zNlgvPzFibl2=	MUXTRW5ITVJ?
HC-1	MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLyTWM2OD1\|M{WuOUBvVQ>?	NIfrZVJUSU6JRWK=
EHEB	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfrOGtKSzVyPUOzO{42OiCwTR?=	M1vYd3NCVkeHUh?=
TUR	NVqxUZdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPyZoxDUUN3ME2zOlMvQTVibl2=	NG\TSXdUSU6JRWK=
LU-139	M3fKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{iwTGlEPTB;M{e4MlAzKG6P	NHLTWHVUSU6JRWK=
NB1	NXPYdlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfIT3RKSzVyPUO4OE41PSCwTR?=	NHLrWI9USU6JRWK=
BB30-HNC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTN6OD6zNkBvVQ>?	M1LHOHNCVkeHUh?=
HAL-01	M33KZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTN6OT6yOkBvVQ>?	M33zZ3NCVkeHUh?=
K5	NIr4SllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7wXGVDUUN3ME20NVEvOzdibl2=	MYPTRW5ITVJ?
MZ2-MEL	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;IV4xKSzVyPUSxN{43PCCwTR?=	MVXTRW5ITVJ?
RXF393	NFfuZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37LSGlEPTB;NEG2MlQ2KG6P	MnTUV2FPT0WU
NCI-H1648	NIDofXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fJVWlEPTB;NEG3MlU{KG6P	NYXPXGF3W0GQR1XS
TE-12	MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF70XYJKSzVyPUSzOE4zPiCwTR?=	NYD1[FNwW0GQR1XS
EoL-1-	M4HncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPYUXZKSzVyPUSzO{46QCCwTR?=	MlThV2FPT0WU
JAR	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TKbWlEPTB;NEO4MlYzKG6P	MXfTRW5ITVJ?
DSH1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DhVmlEPTB;NEW4MlkyKG6P	MmL4V2FPT0WU
NCI-H187	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrZOZZKSzVyPUS2Nk45OSCwTR?=	NEPsRpFUSU6JRWK=
HCE-4	NWX2NWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnLfIw4UUN3ME20O\|cvPjZibl2=	MYjTRW5ITVJ?
8-MG-BA	NH:zUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LJfGlEPTB;NUixMlUzKG6P	M3u2VXNCVkeHUh?=
KLE	NFvoUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTV6NT6yJI5O	NUnNU3J3W0GQR1XS
KNS-42	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTV6Nj64NUBvVQ>?	MnL1V2FPT0WU
MSTO-211H	MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTEXHF4UUN3ME22NFkvPzRibl2=	NFTVfpBUSU6JRWK=
GDM-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTZzND6wPUBvVQ>?	NXHyNG1qW0GQR1XS
TE-1	M2nPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYexN5lGUUN3ME22OFYvOTJibl2=	NGe1SYFUSU6JRWK=
BT-474	M1zITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\SOHdKSzVyPU[0O{4xPiCwTR?=	NEO4RllUSU6JRWK=
KARPAS-45	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTZ2Nz62JI5O	M3\nW3NCVkeHUh?=
MOLT-16	NUmxXnFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3H6WGlEPTB;NkS3Mlk{KG6P	NGfBfJVUSU6JRWK=
KURAMOCHI	M1z6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrpco0{UUN3ME22OVcvPTFibl2=	MmntV2FPT0WU
K-562	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7DO5dlUUN3ME22OlkvPTFibl2=	MkHtV2FPT0WU
EKVX	NYLmXlh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPLTWM2OD14N{KuO\|Ehdk1?	NHK4WWdUSU6JRWK=
GAK	NYHyZYdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTZ5NT6zJI5O	NVTIfFF{W0GQR1XS
NCI-SNU-5	MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HmOmlEPTB;NkmwMlAyKG6P	MWXTRW5ITVJ?
NCI-H2126	NHPSNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrOboNnUUN3ME23NlYvQDdibl2=	MmjSV2FPT0WU
CTV-1	MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzoT3E5UUN3ME23OFQvQSCwTR?=	M4XoeXNCVkeHUh?=
SW962	NF7D[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDSTWM2OD15NEiuOFQhdk1?	MUnTRW5ITVJ?
MONO-MAC-6	NW\JVFdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHCUmNKSzVyPUe1Ok46OyCwTR?=	NEPwRXZUSU6JRWK=
NCI-H748	NIfYdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTd3OD65PUBvVQ>?	MnvnV2FPT0WU
NCI-H524	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2f4T2lEPTB;N{iwMlc{KG6P	NWXQRYt[W0GQR1XS
LS-123	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4THWGlEPTB;N{m1MlY6KG6P	MVfTRW5ITVJ?
NB7	M4H6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRThzND6xOEBvVQ>?	MWXTRW5ITVJ?
LS-1034	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;rUWlEPTB;OEK4Mlk5KG6P	M4LZR3NCVkeHUh?=
TE-5	MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHiyOXRKSzVyPUi4N{42PiCwTR?=	NUTrTpluW0GQR1XS
A704	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\k[WlEPTB;OEm5MlE2KG6P	MX3TRW5ITVJ?
TK10	NHGxepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;hc2RKSzVyPUmxOk4xOyCwTR?=	MVvTRW5ITVJ?
NCI-H345	M1zLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DKfWlEPTB;OUSzMlIzKG6P	NITkbW5USU6JRWK=
CGTH-W-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTl2OD6xN{BvVQ>?	MlXwV2FPT0WU
NCI-H510A	M3XvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLPcYRQUUN3ME25PFUvOTJibl2=	MYDTRW5ITVJ?
NCI-H1963	NEe4U5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETiNXJKSzVyPUGuNFMzQTJizszN	NXj3[JJFW0GQR1XS
SCC-3	NXnHN3lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGG5V5dKSzVyPUGuNFM1OTRizszN	M1LPWnNCVkeHUh?=
EW-11	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofETWM2OD1zLkC4O\|Q{KM7:TR?=	NGT5cW9USU6JRWK=
CPC-N	MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXWT4k2UUN3ME2xMlA5QCEQvF2=	MUnTRW5ITVJ?
NCI-H1417	Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTFwMUKyOkDPxE1?	M1;jT3NCVkeHUh?=
DG-75	NY\MUmd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;DTWM2OD1zLkG2Nlg2KM7:TR?=	NHe3SXVUSU6JRWK=
HD-MY-Z	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\2PGU2UUN3ME2xMlE3PDF4IN88US=>	NUXGT\|lYW0GQR1XS
ATN-1	M1POe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzEOmoxUUN3ME2xMlI3OjB7IN88US=>	MUfTRW5ITVJ?
KM-H2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfDR5FiUUN3ME2xMlI3PDB6IN88US=>	Mn;2V2FPT0WU
NCI-H2081	M4jVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDPTXBQUUN3ME2xMlI3PjN5IN88US=>	NX\xTVBPW0GQR1XS
HL-60	M13SSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXRTVJKSzVyPUGuNlY6PTlizszN	NUjwUXlSW0GQR1XS
DB	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PxS2lEPTB;MT6yO\|I1OiEQvF2=	M1yyUHNCVkeHUh?=
NCI-H1522	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TlOmlEPTB;MT6yPFg5PyEQvF2=	M2nWfHNCVkeHUh?=
AM-38	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzFd5BWUUN3ME2xMlMxPzJizszN	M2nZ[HNCVkeHUh?=
NCI-H446	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFwM{KxNlEh\|ryP	M1qycXNCVkeHUh?=
SU-DHL-1	NHzWWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGi2W4xKSzVyPUGuN\|I5ODFizszN	MVzTRW5ITVJ?
NH-12	M4K2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrXRoZuUUN3ME2xMlM3Ozd2IN88US=>	NGD1T4lUSU6JRWK=
DMS-79	NHizc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37wOmlEPTB;MT6zOlg3PiEQvF2=	M376eXNCVkeHUh?=
NCI-H716	M3K4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTFwM{i5PFYh\|ryP	NF3lPJBUSU6JRWK=
ML-2	NHnOdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1npRWlEPTB;MT60NVUzQSEQvF2=	Ml3kV2FPT0WU
NB10	M1nSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPWTWM2OD1zLkS2OlMzKM7:TR?=	MVLTRW5ITVJ?
ONS-76	NWLNcHNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NISwUWdKSzVyPUGuOVM2PjlizszN	MXjTRW5ITVJ?
LOUCY	NHnmSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH70XW5KSzVyPUGuOVQ3PTdizszN	MnToV2FPT0WU
SCLC-21H	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rzZmlEPTB;MT61PFU5OiEQvF2=	MX;TRW5ITVJ?
TGW	MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\oWWlEPTB;MT62N\|k4PSEQvF2=	MVrTRW5ITVJ?
LXF-289	NXnWNZBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXNNW9KSzVyPUGuO\|MzPjhizszN	NILqNVBUSU6JRWK=
BB49-HNC	M3XOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnWyTWM2OD1zLkezOVg3KM7:TR?=	MmTNV2FPT0WU
NCI-H747	NInm[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fjeWlEPTB;MT63OVM1PiEQvF2=	MULTRW5ITVJ?
LU-165	NIfvZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojjTWM2OD1zLki0PVg3KM7:TR?=	NVTQdWExW0GQR1XS
OMC-1	NYruTJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3WwfGlEPTB;MT65OVA3PiEQvF2=	NILYRVdUSU6JRWK=
RCC10RGB	NX6wV4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\pTWM2OD1zLkm1PFE4KM7:TR?=	M1PyVXNCVkeHUh?=
SW684	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTFwOU[wPVkh\|ryP	NHHhXY5USU6JRWK=
TE-8	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LpVWlEPTB;Mj6wOVU2QSEQvF2=	NVTWWmtqW0GQR1XS
SK-N-DZ	NXn6[YVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTJwMUOyO\|Qh\|ryP	M2POc3NCVkeHUh?=
EVSA-T	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTJwMUezNVUh\|ryP	NF\sepFUSU6JRWK=
KASUMI-1	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnLNXF7UUN3ME2yMlE5QDF3IN88US=>	M1\GeXNCVkeHUh?=
NKM-1	NWHFRZlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17MNGlEPTB;Mj6yOVQ4OiEQvF2=	NY\tW4RwW0GQR1XS
CAL-148	M3fscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzETWM2OD1{LkOzOlE1KM7:TR?=	MWnTRW5ITVJ?
NCI-H64	NGCxWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF22NVhKSzVyPUKuN\|QzOzJizszN	NH7wOYpUSU6JRWK=
KNS-81-FD	M{f1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJwM{[2NkDPxE1?	NYjVfVlqW0GQR1XS
KM12	M1Hzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnSbXJOUUN3ME2yMlQxQDN7IN88US=>	MmriV2FPT0WU
SW954	NVHjd2szT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrPdY1KSzVyPUKuOFc4PzlizszN	NFy1RXVUSU6JRWK=
NCI-H1395	NXXiZlZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPJ[2pKSzVyPUKuOVI3PDVizszN	NITIU2pUSU6JRWK=
DJM-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnGzTWM2OD1{Lk[wOlMh\|ryP	M4Hhd3NCVkeHUh?=
COLO-668	MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\3VIZKSzVyPUKuPFI3QTVizszN	NHTZWWdUSU6JRWK=
NCI-H1436	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWntRoN1UUN3ME2yMlg2PjF3IN88US=>	Mn;CV2FPT0WU
LB2241-RCC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVu2eFZwUUN3ME2yMlg3QDN7IN88US=>	M32zVXNCVkeHUh?=
GT3TKB	NEXJfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV6zbpdUUUN3ME2yMlg6ODV3IN88US=>	NH3jPVRUSU6JRWK=
COLO-824	NYPYd20zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJwOEm3Olgh\|ryP	NGiyUW9USU6JRWK=
ES1	MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJwOEm4O\|kh\|ryP	NGLvVlRUSU6JRWK=
LB771-HNC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;Ee3d5UUN3ME2yMlkxQTR4IN88US=>	MUDTRW5ITVJ?
GI-ME-N	NFvn[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfVTWM2OD1\|LkCwPVA1KM7:TR?=	NUm3b5RZW0GQR1XS
NALM-6	M{XPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTNwMEC5N\|Mh\|ryP	NV\Sdlh5W0GQR1XS
LU-134-A	M{HpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTNwMEW0NlUh\|ryP	MUTTRW5ITVJ?
DMS-153	M3fBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTNwMEW4NlQh\|ryP	NXj3SFhyW0GQR1XS
MZ1-PC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTNwMEmwO\|gh\|ryP	Mn\RV2FPT0WU
NCI-H1155	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPJTWM2OD1\|LkGxOlEh\|ryP	NVj4NoNtW0GQR1XS
CAS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXu0d4lbUUN3ME2zMlE{PzB5IN88US=>	MVnTRW5ITVJ?
D-502MG	M2jOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfxTHhjUUN3ME2zMlE1OzlizszN	MV3TRW5ITVJ?
NCI-H2141	NX7tcItPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITydFhKSzVyPUOuNVc1PTJizszN	NH[xeGNUSU6JRWK=
NB6	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYS2SYlsUUN3ME2zMlE5OjV7IN88US=>	MWTTRW5ITVJ?
NCCIT	Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnUOWZ[UUN3ME2zMlIyQDB7IN88US=>	M1TVSHNCVkeHUh?=
NB69	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPjdmdKSzVyPUOuN\|E5QTFizszN	MoW1V2FPT0WU
JVM-2	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\CTWM2OD1\|LkO2OFM{KM7:TR?=	MUDTRW5ITVJ?
K052	M1XLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\OeFZbUUN3ME2zMlM4QTZ6IN88US=>	M4TscXNCVkeHUh?=
HCC2157	MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXwT2FKSzVyPUOuOVMzOjhizszN	MWDTRW5ITVJ?
KMOE-2	MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLwTWM2OD1\|LkW0NlQzKM7:TR?=	NXHr[m06W0GQR1XS
SF268	NHzqdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjBTWM2OD1\|LkexOVU1KM7:TR?=	NFjTXW5USU6JRWK=
CHP-126	NHH2fGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jpOGlEPTB;Mz63OlQ2QCEQvF2=	NFm0Vm5USU6JRWK=
CP66-MEL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4iwNmlEPTB;Mz63PVA6PCEQvF2=	MYrTRW5ITVJ?
NCI-H69	Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTRwMEG5N\|Yh\|ryP	NYT6bmpMW0GQR1XS
A253	NILsUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTRwMEKxNFEh\|ryP	M1PuOnNCVkeHUh?=
NB14	NFjQSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlO4TWM2OD12LkGwOFc6KM7:TR?=	NH3Yb4FUSU6JRWK=
NCI-H1694	MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjFTWM2OD12LkGzNVEzKM7:TR?=	MWPTRW5ITVJ?
NCI-H2196	NXrDZVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTRwMUexOlkh\|ryP	NEf2cXdUSU6JRWK=
TE-9	M36xO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHX6WZdKSzVyPUSuNVc2QDJizszN	M3;uS3NCVkeHUh?=
D-283MED	NWD4T4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTRwMUi4OEDPxE1?	MknyV2FPT0WU
OCI-AML2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrhb2pEUUN3ME20MlE6PDh7IN88US=>	M2XIfHNCVkeHUh?=
D-263MG	NHrGeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXW0ZYluUUN3ME20MlIzQTZzIN88US=>	M3TMeXNCVkeHUh?=
MPP-89	NFX3Z2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLTZoxTUUN3ME20MlI4OzB2IN88US=>	MWDTRW5ITVJ?
LAMA-84	M4C2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fnWWlEPTB;ND6zNFQzOSEQvF2=	NF20VpNUSU6JRWK=
LB373-MEL-D	NFPqb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPPV2VKSzVyPUSuN\|Y4QDlizszN	NVfaXVlYW0GQR1XS
UACC-257	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3qwNWlEPTB;ND6zPVU{PCEQvF2=	NXXaO3dbW0GQR1XS
MC-CAR	NHXKd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTRwNEO5PUDPxE1?	MXjTRW5ITVJ?
COLO-320-HSR	MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3f2ZmlEPTB;ND60OFQzPyEQvF2=	MWHTRW5ITVJ?
P30-OHK	M1\UOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPHTWM2OD12Lk[2OVgyKM7:TR?=	MknQV2FPT0WU
UACC-812	M4P0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVe2UZgzUUN3ME20MlY6OTZzIN88US=>	MlfaV2FPT0WU
CTB-1	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLLTWM2OD12LkexOVU2KM7:TR?=	NITUcJJUSU6JRWK=
ALL-PO	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2D1RmlEPTB;ND64OFA4PyEQvF2=	NVXhSVRoW0GQR1XS
SK-MEL-2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUe3RVZvUUN3ME20Mlg3QTV3IN88US=>	Ml3HV2FPT0WU
TC-YIK	M{fG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;kfmlEPTB;ND65O\|k1OiEQvF2=	MXjTRW5ITVJ?
NCI-H1882	MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLCTWM2OD13LkCyNFAyKM7:TR?=	M2LHRnNCVkeHUh?=
MHH-CALL-2	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHX3WJVKSzVyPUWuNFUxPDJizszN	NHPsNZlUSU6JRWK=
U-87-MG	M1LPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTTTWM2OD13LkC5OFY3KM7:TR?=	M1LQVXNCVkeHUh?=
NCI-H1092	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fzbmlEPTB;NT6yOlU2PSEQvF2=	MnLIV2FPT0WU
TE-441-T	NVnpTVhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXtblhKSzVyPUWuNlc5OiEQvF2=	NGK5XmtUSU6JRWK=
SK-MEL-1	NXXzNogxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUC5TmFwUUN3ME21MlI6ODR2IN88US=>	M{\kb3NCVkeHUh?=
EW-22	NX3qWpBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorETWM2OD13LkK5OFY3KM7:TR?=	NFm4bGRUSU6JRWK=
MZ7-mel	NHjQPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLYTWM2OD13LkSwOlkyKM7:TR?=	MnnSV2FPT0WU
LP-1	M3ezTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTzd5JPUUN3ME21MlQyOjlzIN88US=>	MVHTRW5ITVJ?
NCI-SNU-16	M2\UfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jBXWlEPTB;NT62OFA4PCEQvF2=	M{P3Z3NCVkeHUh?=
LU-65	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTVwN{[zO\|Mh\|ryP	M1nmO3NCVkeHUh?=
CW-2	MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHiwPJlKSzVyPUWuPFU6PTlizszN	M2DZOXNCVkeHUh?=
WSU-NHL	MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\KTWM2OD13Lkm1NVc1KM7:TR?=	NXPNeVU4W0GQR1XS
IST-MES1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLWWFdpUUN3ME21Mlk2PDR\|IN88US=>	M3rObHNCVkeHUh?=
U-266	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIm1eYxKSzVyPUWuPVgzODJizszN	M2jy[3NCVkeHUh?=
TALL-1	NVXuTldYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTZwMUS2PFgh\|ryP	NHXyUVRUSU6JRWK=
Calu-6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4q4dmlEPTB;Nj6xOVMyPiEQvF2=	NYnEPW9pW0GQR1XS
MMAC-SF	NEnCOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHxTWM2OD14LkG4OVU3KM7:TR?=	NXz4fFdjW0GQR1XS
NCI-H82	NUPPW3RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFuxSpFKSzVyPU[uNlA1QDlizszN	MkHrV2FPT0WU
RS4-11	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jYXmlEPTB;Nj6yOVg6PyEQvF2=	MmPjV2FPT0WU
SNU-C2B	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTZwNEC5Olkh\|ryP	NF\IcFZUSU6JRWK=
BOKU	NFTncIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvHTWM2OD14LkS3OVk4KM7:TR?=	M{C5cHNCVkeHUh?=
C8166	NVzRb\|hIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHPV\|ZKSzVyPU[uOVU6OTJizszN	NWHNfZE6W0GQR1XS
D-247MG	M1TwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfhdXNQUUN3ME23MlA1OzR5IN88US=>	M4e1[3NCVkeHUh?=
EW-18	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTdwMEeyPVIh\|ryP	M3;lSnNCVkeHUh?=
KG-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DURmlEPTB;Nz62Nlc{QCEQvF2=	NYW0SotWW0GQR1XS
REH	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrsc4FKSzVyPUeuOlgyODlizszN	M4HTfHNCVkeHUh?=
U-698-M	M33ZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1z5XWlEPTB;Nz64OFMyPSEQvF2=	Ml:xV2FPT0WU
KP-N-RT-BM-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTdwOUOwNlkh\|ryP	MnLEV2FPT0WU
MS-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTdwOU[wOFEh\|ryP	M2L3SHNCVkeHUh?=
SNU-C1	Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTdwOUixPVIh\|ryP	NH\m[pNUSU6JRWK=
SK-MM-2	M1HWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2j2R2lEPTB;OD6yOlA3PSEQvF2=	NF7XWVZUSU6JRWK=
LAN-6	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDD[YJKSzVyPUiuN\|AxODFizszN	MULTRW5ITVJ?
NEC8	NHvze\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jBSmlEPTB;OD6zNFY6OSEQvF2=	M33OdHNCVkeHUh?=
NCI-H1770	NWfJN4pOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Pzc2lEPTB;OD6zPFAxOiEQvF2=	NFnzfG5USU6JRWK=
D-336MG	M33jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRThwNECxNVYh\|ryP	NYLhPXhqW0GQR1XS
COLO-829	NIHHfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo[0TWM2OD16LkS4PFc6KM7:TR?=	NXvqVWNrW0GQR1XS
LS-513	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTQNGNiUUN3ME24MlU6PTl7IN88US=>	M1rO[nNCVkeHUh?=
YT	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\VOIlmUUN3ME24MlYzPDJ5IN88US=>	M1\aVXNCVkeHUh?=
EW-24	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfYSFg4UUN3ME24Mlc3PTRizszN	NUHGfJV7W0GQR1XS
IST-SL1	NH3lZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnrWlFKSzVyPUiuPFY2PDNizszN	M3jXTXNCVkeHUh?=
CA46	NV;BfllJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRThwOUWwPVgh\|ryP	MX\TRW5ITVJ?
NCI-H1838	MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlP1TWM2OD16Lkm4OlAzKM7:TR?=	M{Xld3NCVkeHUh?=
NCI-H719	NI\oXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnr4TWM2OD17LkK1Nlc6KM7:TR?=	NE[5OXpUSU6JRWK=
HCE-T	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fmdGlEPTB;OT6zNFg2OSEQvF2=	MlS0V2FPT0WU
A498	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGC3UFlKSzVyPUmuN\|YyOjRizszN	M{TySnNCVkeHUh?=
LB831-BLC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPlTWM2OD17Lke2OVIyKM7:TR?=	MXfTRW5ITVJ?
SKM-1	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vIN2lEPTB;OT64OVk3OyEQvF2=	NFfaS5FUSU6JRWK=
THP-1	M2HtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXX5TZVpUUN3ME25Mlk3QTF6IN88US=>	M131cnNCVkeHUh?=
SHP-77	NELTSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTFyLkSwO{DPxE1?	MXjTRW5ITVJ?
EW-3	NX[1W2h3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoS1TWM2OD1zMD62Nlg6KM7:TR?=	M3L1[nNCVkeHUh?=
KY821	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHhTmFTUUN3ME2xNE44PjNizszN	MWDTRW5ITVJ?
NCI-SNU-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPGeZIzUUN3ME2xNU4xOjF5IN88US=>	NHXM[2ZUSU6JRWK=
HCC2218	NYPKNY5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1:1OGlEPTB;MUGuN\|k5PiEQvF2=	MXTTRW5ITVJ?
IM-9	M3H5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfMb3kzUUN3ME2xNU42OTB4IN88US=>	MWrTRW5ITVJ?
NCI-H889	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzUTWM2OD1zMT61N\|E{KM7:TR?=	MkS2V2FPT0WU
HDLM-2	M4\kOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFW0[WtKSzVyPUGyMlQyPTlizszN	MlW2V2FPT0WU
LB2518-MEL	M1fYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTF{Lk[4NVUh\|ryP	MXXTRW5ITVJ?
NCI-H23	NITHeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTF\|LkK0NlUh\|ryP	Mn\6V2FPT0WU
NB17	NWfzR2d[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mny2TWM2OD1zMz60OVc6KM7:TR?=	MmLVV2FPT0WU
NCI-H322M	MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU[0N5llUUN3ME2xOE41ODZ6IN88US=>	NEDwemJUSU6JRWK=
SUP-T1	MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEm1bnJKSzVyPUG0MlQyOyEQvF2=	NUTreZN2W0GQR1XS
ES3	NWe4eVd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjHVmRKSzVyPUG1MlA4ODNizszN	NGDKTYhUSU6JRWK=
ES5	Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIniXnBKSzVyPUG1MlA4QDdizszN	M4LrXXNCVkeHUh?=
NCI-H1650	M{\mUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTF3LkS5O\|kh\|ryP	M3Pn[HNCVkeHUh?=
NCI-H226	NVHPRWk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDWTWM2OD1zNT64O\|Y5KM7:TR?=	NWjwfJlRW0GQR1XS
COR-L88	MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXwT4ZTUUN3ME2xOk4{OTRizszN	NVnSWVZ5W0GQR1XS
SCC-15	NEna[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTF4LkO4Olkh\|ryP	MkjmV2FPT0WU
GOTO	NWLjW2s6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnNTHRiUUN3ME2xOk41Pzl\|IN88US=>	MWrTRW5ITVJ?
SIMA	NIP6[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rncmlEPTB;MU[uOFgxOiEQvF2=	MYLTRW5ITVJ?
NCI-H1299	M2DRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGf4NotKSzVyPUG3MlE2QTFizszN	NY\BU2JEW0GQR1XS
NCI-H1581	NXKyUod5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVqxdYU6UUN3ME2xO{41OjF7IN88US=>	MlfwV2FPT0WU
MHH-NB-11	NGmwPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTF5Lkm2PFMh\|ryP	MXrTRW5ITVJ?
MFM-223	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInteGZKSzVyPUG4MlA2OzhizszN	MWLTRW5ITVJ?
ES7	M4fXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrReZVKSzVyPUG4MlU1OzFizszN	Mo\ZV2FPT0WU
JVM-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTF6LkexO{DPxE1?	Mn3LV2FPT0WU
RL	Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\TeGlEPTB;MkCuN\|g5KM7:TR?=	MkfMV2FPT0WU
EC-GI-10	NYLQb3lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnjTWM2OD1{MT6yNFQyKM7:TR?=	M3vJdnNCVkeHUh?=
LNCaP-Clone-FGC	NGP5Z3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLmTWM2OD1{MT62O\|Y5KM7:TR?=	Mkf1V2FPT0WU
IMR-5	NF\ueG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUL2fHFtUUN3ME2yNU45PDl2IN88US=>	M3frb3NCVkeHUh?=
KP-N-YS	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGf5e4pKSzVyPUKxMlg4PSEQvF2=	NIPtUIdUSU6JRWK=
Mo-T	NXXQS41mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJ{LkKxPFUh\|ryP	MYPTRW5ITVJ?
NCI-H128	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLETWM2OD1{Mz61PFU{KM7:TR?=	MXPTRW5ITVJ?
RH-1	NFvDe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWL5b45LUUN3ME2yN{44QDZ4IN88US=>	NWjzcnI2W0GQR1XS
NCI-H2171	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmS0TWM2OD1{ND6yOFg2KM7:TR?=	M1n5bXNCVkeHUh?=
RPMI-8866	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfGTWM2OD1{Nj63OFIh\|ryP	MY\TRW5ITVJ?
SK-N-FI	NGThWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M332W2lEPTB;MkeuN\|gyOSEQvF2=	MmfHV2FPT0WU
LOXIMVI	NVzlOFhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTJ5LkiwOVEh\|ryP	MYfTRW5ITVJ?
P31-FUJ	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfabmdKSzVyPUOxMlU{PzRizszN	MlnYV2FPT0WU
KMS-12-PE	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rDOWlEPTB;NEmuOVMxOiEQvF2=	NUexUFlvW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR(S2448)/mTOR; PubMed: 23991038 PLoS One MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.	23991038
Growth inhibition assay	Cell proliferation; PubMed: 30393233 Biosci Rep (A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.	30393233
Histomorphology	Haematoxylin & Eosin; PubMed: 28418837 Oncotarget Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.	28418837
Immunofluorescence	NeuN; PubMed: 28418837 Oncotarget Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown. p62/Beclin; PubMed: 28819214 Sci Rep (C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody.	28418837 28819214
ELISA	Type III collagen/Fibronectin; PubMed: 23364979 Yonsei Med J (A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.	23364979

In vivo

Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. ^[4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. ^[5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. ^[6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. ^[7]

Protocol

Kinase Assay: ^[1]	+ Expand Immunoblotting for the mTOR kinase assay: HEK293 cells are plated at 2-2.5×10⁵ cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research: ^[3]	+ Expand Cell lines: U87-MG, T98G, and U373-MG Concentrations: Dissolved in DMSO, final concentrations ~25 μM Incubation Time: 72 hours Method: Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope. (Only for Reference)
Animal Research: ^[7]	+ Expand Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O) Dosages: ~4 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	20 mg/mL (21.87 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Rapamycin (Sirolimus) SDF

Molecular Weight	914.18
Formula	C₅₁H₇₉NO₁₃
CAS No.	53123-88-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	AY 22989，NSC-2260804

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03433183	Recruiting	Drug: Selumetinib\|Drug: Sirolimus	Malignant Peripheral Nerve Sheath Tumors\|Neurofibromatosis 1	Sarcoma Alliance for Research through Collaboration\|United States Department of Defense\|AstraZeneca	October 2 2019	Phase 2
NCT03933904	Recruiting	Drug: Sirolimus	Castleman Disease\|Castleman''s Disease Multicentric	University of Pennsylvania	September 25 2019	Phase 2
NCT03972592	Recruiting	Drug: Topical 0.1% Sirolimus\|Drug: Topical Vehicle	Vascular Malformations\|Lymphatic Malformation	University Hospital Tours\|University Hospital Angers	June 5 2019	Phase 2
NCT03811717	Completed	Other: FAST+EX\|Other: FAST	Skeletal Muscle Energetics	Queen''s University\|University of Waterloo	January 14 2019	Not Applicable
NCT03765944	Completed	Drug: sirolimus	Bioequivalence Study	Nobelpharma	December 5 2018	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Pan mTOR inhibitor

KU-0063794 : mTORC1 and mTORC2, IC50=~10 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.
Classic mTOR Inhibitor

BEZ235 (NVP-BEZ235, Dactolisib) : Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Rapamycin (Sirolimus)

Cited by 239 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Rapamycin (Sirolimus) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Choose Your Country or Region

By Signaling Pathways

By product type

Rapamycin (Sirolimus)

Cited by 239 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Rapamycin (Sirolimus) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)